Literature DB >> 21123638

Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer.

Sandhya Pruthi1, Bobbie S Gostout, Noralane M Lindor.   

Abstract

Women with a germline BRCA1 or BRCA2 mutation or a hereditary predisposition for breast and ovarian cancer have substantial risk of breast or ovarian cancer relative to the general US population. Health care professionals can be instrumental in identifying women at increased risk through obtaining a comprehensive family history and becoming familiar with family history characteristics associated with hereditary predisposition for breast and ovarian cancer. BRCA carriers and women at very high risk benefit from multidisciplinary, individualized medical evaluation and risk management. We conducted a search of MEDLINE from 1989 through 2010 for the terms BRCA1, BRCA2, breast cancer, ovarian cancer, risk assessment, and genetic testing. We reviewed abstracts and relevant randomized and prospective studies that included very high-risk patient groups and BRCA mutation carriers. Herein, we review the role of genetic consultation and BRCA testing and the comprehensive, multisystem recommendations for risk management. A multidisciplinary approach offers the ability to educate those at very high risk about cancer prevention, reduce cancer risk, maximize early detection of breast and ovarian cancer, and improve survival.

Entities:  

Mesh:

Year:  2010        PMID: 21123638      PMCID: PMC2996153          DOI: 10.4065/mcp.2010.0414

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  77 in total

1.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Authors:  Victor G Vogel; Joseph P Costantino; D Lawrence Wickerham; Walter M Cronin; Reena S Cecchini; James N Atkins; Therese B Bevers; Louis Fehrenbacher; Eduardo R Pajon; James L Wade; André Robidoux; Richard G Margolese; Joan James; Scott M Lippman; Carolyn D Runowicz; Patricia A Ganz; Steven E Reis; Worta McCaskill-Stevens; Leslie G Ford; V Craig Jordan; Norman Wolmark
Journal:  JAMA       Date:  2006-06-05       Impact factor: 56.272

2.  Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Authors:  Timothy R Rebbeck; Tara Friebel; Theresa Wagner; Henry T Lynch; Judy E Garber; Mary B Daly; Claudine Isaacs; Olufunmilayo I Olopade; Susan L Neuhausen; Laura van 't Veer; Rosalind Eeles; D Gareth Evans; Gail Tomlinson; Ellen Matloff; Steven A Narod; Andrea Eisen; Susan Domchek; Katrina Armstrong; Barbara L Weber
Journal:  J Clin Oncol       Date:  2005-10-11       Impact factor: 44.544

3.  Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS).

Authors:  Nadine Andrieu; David E Goldgar; Douglas F Easton; Matti Rookus; Richard Brohet; Antonis C Antoniou; Susan Peock; Gareth Evans; Diana Eccles; Fiona Douglas; Catherine Noguès; Marion Gauthier-Villars; Agnès Chompret; Flora E Van Leeuwen; Irma Kluijt; Javier Benitez; Brita Arver; Edith Olah; Jenny Chang-Claude
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

4.  Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance.

Authors:  Marlene H Frost; Jeffrey M Slezak; Nho V Tran; Constance I Williams; Joanne L Johnson; John E Woods; Paul M Petty; John H Donohue; Clive S Grant; Jeff A Sloan; Thomas A Sellers; Lynn C Hartmann
Journal:  J Clin Oncol       Date:  2005-10-03       Impact factor: 44.544

5.  Diagnostic performance of digital versus film mammography for breast-cancer screening.

Authors:  Etta D Pisano; Constantine Gatsonis; Edward Hendrick; Martin Yaffe; Janet K Baum; Suddhasatta Acharyya; Emily F Conant; Laurie L Fajardo; Lawrence Bassett; Carl D'Orsi; Roberta Jong; Murray Rebner
Journal:  N Engl J Med       Date:  2005-09-16       Impact factor: 91.245

6.  Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Authors:  Kristin Anderson; Judith S Jacobson; Daniel F Heitjan; Joshua Graff Zivin; Dawn Hershman; Alfred I Neugut; Victor R Grann
Journal:  Ann Intern Med       Date:  2006-03-21       Impact factor: 25.391

7.  Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians.

Authors:  A Nkondjock; A Robidoux; Y Paredes; S A Narod; P Ghadirian
Journal:  Breast Cancer Res Treat       Date:  2006-03-16       Impact factor: 4.872

8.  Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study.

Authors:  Trond M Michelsen; Are H Pripp; Serena Tonstad; Claes G Tropé; Anne Dørum
Journal:  Eur J Cancer       Date:  2008-11-12       Impact factor: 9.162

9.  Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Authors:  Timothy R Rebbeck; Noah D Kauff; Susan M Domchek
Journal:  J Natl Cancer Inst       Date:  2009-01-13       Impact factor: 13.506

10.  Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Joanne Kotsopoulos; Olufunmilayo I Olopado; Parviz Ghadirian; Jan Lubinski; Henry T Lynch; Claudine Isaacs; Barbara Weber; Charmaine Kim-Sing; Peter Ainsworth; William D Foulkes; Andrea Eisen; Ping Sun; Steven A Narod
Journal:  Breast Cancer Res       Date:  2005-08-19       Impact factor: 6.466

View more
  52 in total

Review 1.  Impact of germline and somatic BRCA1/2 mutations: tumor spectrum and detection platforms.

Authors:  H Wu; X Wu; Z Liang
Journal:  Gene Ther       Date:  2017-08-03       Impact factor: 5.250

2.  Practical considerations to guide development of access controls and decision support for genetic information in electronic medical records.

Authors:  Diana C Darcy; Eleanor T Lewis; Kelly E Ormond; David J Clark; Jodie A Trafton
Journal:  BMC Health Serv Res       Date:  2011-11-02       Impact factor: 2.655

3.  Giving and withholding of information following genomic screening: challenges identified in a study of primary care physicians in Estonia.

Authors:  Liis Leitsalu; Laura Hercher; Andres Metspalu
Journal:  J Genet Couns       Date:  2011-12-08       Impact factor: 2.537

4.  Fine mapping of 14q24.1 breast cancer susceptibility locus.

Authors:  Phoebe Lee; Yi-Ping Fu; Jonine D Figueroa; Ludmila Prokunina-Olsson; Jesus Gonzalez-Bosquet; Peter Kraft; Zhaoming Wang; Kevin B Jacobs; Meredith Yeager; Marie-Josèphe Horner; Susan E Hankinson; Amy Hutchinson; Nilanjan Chatterjee; Montserrat Garcia-Closas; Regina G Ziegler; Christine D Berg; Saundra S Buys; Catherine A McCarty; Heather Spencer Feigelson; Michael J Thun; Ryan Diver; Ross Prentice; Rebecca Jackson; Charles Kooperberg; Rowan Chlebowski; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Margaret Tucker; Joseph F Fraumeni; Robert N Hoover; Gilles Thomas; David J Hunter; Stephen J Chanock
Journal:  Hum Genet       Date:  2011-09-30       Impact factor: 4.132

5.  Nicotinamide adenine dinucleotide (NAD) may affect DNA methyltransferase 1 through regulation of BRCA1 in ovarian cancer.

Authors:  Yuan-Yuan Fang; Fang-Fang Bi; Yi-Ming Zhou; Wu-Ping Sun; Chun-Yan Li; Qian Liu; Yue Zhao; Da Li
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Clinical Pearls in breast disease.

Authors:  Sandhya Pruthi; John B Bundrick; Scott C Litin
Journal:  Mayo Clin Proc       Date:  2012-09-12       Impact factor: 7.616

7.  Variants of uncertain significance in BRCA testing: evaluation of surgical decisions, risk perception, and cancer distress.

Authors:  J O Culver; C D Brinkerhoff; J Clague; K Yang; K E Singh; S R Sand; J N Weitzel
Journal:  Clin Genet       Date:  2013-02-20       Impact factor: 4.438

8.  Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.

Authors:  Murray Joseph Casey; Todd A Salzman
Journal:  Linacre Q       Date:  2018-07-20

9.  BRCA1 as a nicotinamide adenine dinucleotide (NAD)-dependent metabolic switch in ovarian cancer.

Authors:  Da Li; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Xiu-Xia Wang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.

Authors:  Da Li; Fang-Fang Bi; Na-Na Chen; Ji-Min Cao; Wu-Ping Sun; Yi-Ming Zhou; Chun-Yan Li; Qing Yang
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.